Marksans Pharma Limited (BOM: 524404)

Market Cap	138.17B
Revenue (ttm)	23.79B
Net Income (ttm)	3.47B
Shares Out	n/a
EPS (ttm)	7.65
PE Ratio	39.82
Forward PE	n/a
Dividend	0.60 (0.19%)
Ex-Dividend Date	Sep 17, 2024

Volume	71,534
Open	313.15
Previous Close	320.95
Day's Range	311.65 - 317.60
52-Week Range	126.05 - 358.50
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Marksans Pharma

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, upper respiratory, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamin...

• Industry: Pharmaceutical Preparations
• Founded: 1992
• Employees: 1,141
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524404

Financial Performance

In 2023, Marksans Pharma's revenue was 21.77 billion, an increase of 17.56% compared to the previous year's 18.52 billion. Earnings were 3.14 billion, an increase of 17.80%.